Cara Therapeutics, Inc. (NASDAQ: CARA) Q3 2021 earnings call dated Nov. 08, 2021 Corporate Participants: Will Gramig -- Senior Analyst Derek Chalmers -- Chief Executive Officer,
Cara Therapeutics Inc.
-(CARA)
Get the latest Cara Therapeutics Inc. (CARA) stock news, earnings analysis, earnings conference calls, earnings transcripts from AlphaStreet.
Cara Therapeutics, Inc. CARA) Q2 2021 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ: CARA) Q2 2021 earnings call dated Aug. 09, 2021 Corporate Participants: Cole Herlitz-Ferguson -- Investor Relations Derek Chalmers -- Chief Executive Officer,
Cara Therapeutics Inc (CARA) Q1 2021 Earnings Call Transcript
Cara Therapeutics Inc (NASDAQ:CARA) Q1 2021 earnings call dated May. 10, 2021. Corporate Participants: Jack Hildick-Smith -- Investor Relations Derek Chalmers -- Chief Executive Officer, President,
Cara Therapeutics Inc. (NASDAQ: CARA) Q1 2020 Earnings Call Transcript
Cara Therapeutics Inc. (CARA) Q1 2020 earnings call dated May 11, 2020 Corporate Participants: Jack Hildick-Smith -- Investor Relations Derek Chalmers -- Chief Executive Officer, President,
Cara Therapeutics Inc. (NASDAQ: CARA) Q4 2019 Earnings Call Transcript
Cara Therapeutics Inc (NASDAQ: CARA) Q4 2019 Earnings Conference Call Final Transcript Corporate participants: Jack Hildick-Smith -- Investor Relations Derek Chalmers -- President, Director and Chief Executive
Cara Therapeutics’ (CARA) loss expands in Q3 on higher costs
Cara Therapeutics' (NASDAQ: CARA) loss widened in the third quarter of 2019, hurt by higher expenses. Cara Therapeutics posted a loss of
Cara Therapeutics Q1 loss widens but beats estimates
Cara Therapeutics Inc. (NASDAQ: CARA) reported a wider loss in the first quarter of 2019 due to higher costs and expenses. The bottom
Earnings: Trevena slips on wider-than-expected Q4 loss
Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market trading. Helped
Cara Therapeutics stock surges after reporting Q4 earnings results
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the fourth quarter
Earnings Preview Q4: Cara Therapeutics’ success in 2019 will depend on Korsuva trial outcomes
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after the regular